Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011570 (
depression
)
172,036
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effects of acute and chronic restraint stresses on the brain histamine level and
histamine N-methyltransferase
activity in Fischer rat brain were studied. The acute restraint stress increased the histamine levels in the diencephalon and nucleus accumbens, and increased the
histamine N-methyltransferase
activities in the nucleus accumbens and striatum. The chronic restraint stress also increased
histamine N-methyltransferase
activities in the nucleus accumbens and striatum. These results indicate that the acute and chronic restraint stresses increase the brain histamine turnover, which may partly relate to the vulnerability for stress-induced anxiety and
depression
.
...
PMID:Effects of the acute and chronic restraint stresses on the central histaminergic neuron system of Fischer rat. 1020 52
Recently developed multi-targeted ligands are novel drug candidates able to interact with monoamine oxidase A and B; acetylcholinesterase and butyrylcholinesterase; or with
histamine N-methyltransferase
and histamine H3-receptor (H3R). These proteins are drug targets in the treatment of
depression
, Alzheimer's disease, obsessive disorders, and Parkinson's disease. A probabilistic method, the Parzen-Rosenblatt window approach, was used to build a "predictor" model using data collected from the ChEMBL database. The model can be used to predict both the primary pharmaceutical target and off-targets of a compound based on its structure. Molecular structures were represented based on the circular fingerprint methodology. The same approach was used to build a "predictor" model from the DrugBank dataset to determine the main pharmacological groups of the compound. The study of off-target interactions is now recognised as crucial to the understanding of both drug action and toxicology. Primary pharmaceutical targets and off-targets for the novel multi-target ligands were examined by use of the developed cheminformatic method. Several multi-target ligands were selected for further study, as compounds with possible additional beneficial pharmacological activities. The cheminformatic targets identifications were in agreement with four 3D-QSAR (H3R/D1R/D2R/5-HT2aR) models and by in vitro assays for serotonin 5-HT1a and 5-HT2a receptor binding of the most promising ligand (71/MBA-VEG8).
...
PMID:Predicting targets of compounds against neurological diseases using cheminformatic methodology. 2542 29